靶向肠道菌群治疗胃肠疾病研究进展  

Microbiota-targeted therapeutics in gastrointestinal diseases

作　　者：邵好青 谭周进[1] Hao-Qing Shao;Zhou-Jin Tan(Hunan University of Chinese Medicine,Changsha 410208,Hunan Province,China)

机构地区：[1]湖南中医药大学,湖南省长沙市410208

出　　处：《世界华人消化杂志》2021年第15期841-848,共8页World Chinese Journal of Digestology

基　　金：国家自然科学基金,No.81874460.

摘　　要：近年来,越来越多的疾病被发现与肠道菌群失调相关,特别是近5年来一些颠覆性的发现使得肠道菌群成为健康、疾病领域的热点问题.作为机体生物过程的重要协调者以及多种疾病发生发展过程中的共同参与者,加之其组成和功能的可塑性,肠道菌群逐渐成为一个极富吸引力的预防和治疗疾病的靶标而引起研究者的高度重视.本文就肠道菌群与肠易激综合征、IBD和结直肠癌的关系进行了整理,并介绍了在胃肠病中以肠道菌群为靶向的治疗策略的现状,以期为靶向肠道菌群治疗策略的应用提供借鉴.In recent years,more and more diseases have been found to be related to dysbiosis.In particular,some disruptive discoveries in the past five years have made gut microbiota a hot topic in the field of health and diseases.As an important coordinator of biological processes and a common participant in the occurrence and development of multiple diseases,coupled with the plasticity of its composition and function,the gut microbiota has gradually become an attractive target for the intervention and management of diseases,arousing great attention of researchers.In this paper,we summarize the relationship between gut microbiota and irritable bowel syndrome,inflammatory bowel disease,and colorectal cancer.Then,we introduce the current status of microbiota-targeted therapeutics in gastrointestinal diseases.

关 键 词：肠道菌群 肠易激综合征 炎症性肠病 结直肠癌 靶向菌群疗法 

分 类 号：R57[医药卫生—消化系统]